摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-methoxy-5-(2-methoxyethoxy)benzoate | 900155-47-7

中文名称
——
中文别名
——
英文名称
methyl 3-methoxy-5-(2-methoxyethoxy)benzoate
英文别名
——
methyl 3-methoxy-5-(2-methoxyethoxy)benzoate化学式
CAS
900155-47-7
化学式
C12H16O5
mdl
——
分子量
240.256
InChiKey
DCISFOOFJODZPV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    54
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    3,5-二羟基苯甲酸甲酯硫酸 、 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 4.0h, 生成 methyl 3-methoxy-5-(2-methoxyethoxy)benzoate
    参考文献:
    名称:
    [EN] N-PIPERIDIN-4-YL DERIVATIVES
    [FR] DÉRIVÉS DE N-PIPÉRIDINE-4-YL
    摘要:
    该发明涉及具有一般式I的N-哌啶-4-基衍生物或其药用可接受的盐,以及包含相同的药物组合物,以及利用所述N-哌啶-4-基衍生物用于治疗和预防子宫内膜异位症,用于治疗和预防更年前和更年期激素依赖性乳腺癌,用于避孕,或用于治疗子宫肌瘤或其他与月经有关的疾病。
    公开号:
    WO2013041457A1
点击查看最新优质反应信息

文献信息

  • 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES
    申请人:Masuya Keiichi
    公开号:US20100029647A1
    公开(公告)日:2010-02-04
    3,4(,5)-substituted tetrahydropyridine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4(,5)-substituted tetrahydropyridine compound, and/or a method of treatment comprising administering a 3,4(,5)-substituted tetrahydropyridine compound, a method for the manufacture of a 3,4(,5)-substituted tetrahydropyridine compound, and novel intermediates and partial steps for its synthesis. The 3,4(,5)-substituted tetrahydropyridine compounds have the formula I wherein the substituents and symbols are as described in the specification.
    3,4(,5)-取代四氢吡啶化合物,这些化合物用于温血动物的诊断和治疗,特别是用于治疗依赖于肾素活性的疾病;该类化合物用于制备治疗依赖于肾素活性疾病的制药配方;该类化合物用于治疗依赖于肾素活性的疾病;包含3,4(,5)-取代四氢吡啶化合物的制药配方,和/或包括给予3,4(,5)-取代四氢吡啶化合物的治疗方法,以及制备3,4(,5)-取代四氢吡啶化合物的方法,以及其合成的新中间体和部分步骤。3,4(,5)-取代四氢吡啶化合物的化学式为I,其中取代基和符号如说明书所述。
  • N-PIPERIDIN-4-YL DERIVATIVES
    申请人:Huisman Ines
    公开号:US20140329822A1
    公开(公告)日:2014-11-06
    The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.
    本发明涉及一种具有通式I的N-哌啶-4-基衍生物或其药学上可接受的盐,以及包含该衍生物的制药组合物,以及利用该N-哌啶-4-基衍生物治疗和预防子宫内膜异位症,治疗和预防绝经前和围绝经期激素依赖性乳腺癌,用于避孕或治疗子宫肌瘤或其他与月经有关的疾病。
  • N-piperidin-4-yl derivatives
    申请人:Huisman Ines
    公开号:US08993757B2
    公开(公告)日:2015-03-31
    The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.
    本发明涉及一种具有通式I的N-哌啶-4-基衍生物或其药学上可接受的盐,以及包含它们的制药组合物,以及利用该N-哌啶-4-基衍生物用于治疗和预防子宫内膜异位症,治疗和预防绝经前和围绝经期激素依赖性乳腺癌,避孕,或治疗子宫肌瘤或其他与月经有关的疾病的用途。
  • Organic Compounds
    申请人:Ehara Takeru
    公开号:US20090192148A1
    公开(公告)日:2009-07-30
    The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.
    本发明涉及3,5-取代哌啶化合物,这些化合物用于诊断和治疗温血动物,特别是用于治疗依赖肾素活性的疾病(=失调);该类化合物用于制备治疗依赖肾素活性疾病的制剂;该类化合物用于治疗依赖肾素活性的疾病;包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法,以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I',其中R1、R2、T、R3和R4在规范中有定义。
  • 3 , 5-substitued piperidine compounds as renin inhibitors
    申请人:Novartis AG
    公开号:EP2420491A1
    公开(公告)日:2012-02-22
    The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.
    本发明涉及3,5-取代的哌啶化合物,这些化合物用于温血动物的诊断和治疗,特别是用于治疗依赖于肾素活性的疾病(=紊乱);使用该类化合物制备药物制剂,用于治疗依赖于肾素活性的疾病;该类化合物在治疗依赖于肾素活性的疾病中的用途;包含 3,5-取代的哌啶化合物的药物制剂,和/或包括施用 3,5-取代的哌啶化合物的治疗方法,3,5-取代的哌啶化合物的制造方法,及其合成的新型中间体和部分步骤。 这些化合物(也可以以盐的形式存在)具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义,R6 为 OH。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐